In people, a moderate reduction (5–10%) in body weight is associated with clinical improvements in lipid profiles (e.g., triglicerides [TG], total cholesterol [TC]), other obesity-related cardiometabolic risk factors (e.g., insulin, fasting plasma glucose levels [FPG]), and descreases the risk of heart failure, stroke, chronic kidney disease, diabetes, and obstructive sleep apnea [38, 39]. The gene discussed is INS; the disease is obesity disorder.